Clinical trials: ST-elevation Myocardial Infarction (STEMI)
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.
Acute Myocardial Infarction
Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction
Hypothesis: Based on available pharmacokinetic data from healthy volunteers we hypothesize that the administration of a cumulative dose of 210μg of the continuous erythropoietin receptor activator, Mircera® (Roche), during 3…
- Trial name
- BEATSTEMIPi (NCT01093820)
- Testing
- methoxy-polyethyleneglycol epoetin beta
- Where
- Switzerland
- Volunteers
- 8 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute Myocardial Infarction With ST Elevation
Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers
The aim of the present study was to investigate the efficacy of ischemic postconditioning in acute myocardial infarction patients. The safety of patients enrolled in the study was ensured during the entire study.
- Trial name
- NCT04824716
- Testing
- Postconditioning, Percutaneous coronary intervention
- Where
- 3 sites in Hungary
- Volunteers
- 100 people
- Sponsor
- Peter Ferdinandy
Acute Myocardial Infarct
Intracoronary Injection of Epo After Myocardial Infarct "Intra-CO-EpoMI"
Primary endpoint: Is intracoronary injection of a single dose of darbepoetin alpha, during reperfusion in patients hospitalized for ST segment elevation myocardial infarction (STEMI), able to reduce infarct size ? In in vivo…
- Trial name
- NCT01043991
- Testing
- Darbepoetin alfa
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Montpellier
STEMI
Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon Treatment for STEMI Patients：a Prospective, Multicenter, Randomized Controlled Trial
Objectives: The present study aimed to investigate the difference in late luminal loss (LLL) at 9-month after drug-coated balloon (DCB) treatment with intravascular ultrasound (IVUS) versus angiography for ST-segment elevated…
- Trial name
- NCT04475978
- Testing
- IVUS-guide DCB PTCA, Angio-guide DCB PTCA
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Xiamen Cardiovascular Hospital, Xiamen University
Acute Myocardial Infarction
Revascularization Strategies for STEMI; The CMR Endpoint Study
Revascularization strategies for ST elevation myocardial infarction (STEMI) study (ASSIST-CMR) will compare the effects of two revascularization strategies [same sitting multivessel primary PCI (SS-PCI) and culprit vessel only…
- Trial name
- ASSIST-CMR (NCT01818960)
- Testing
- IRA-PCI, SS-PCI
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Unity Health Toronto
Myocardial Infarction
Warfarin After Anterior ST-Elevation Myocardial Infarction
Following severe heart attacks involving the front wall of the heart (anterior myocardial infarction), patients are at risk of developing blood clots in the main pumping chamber that can cause a stroke.
- Trial name
- NCT00662467
- Testing
- aspirin + clopidogrel, aspirin + clopidogrel + warfarin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
STEMI - ST Elevation Myocardial Infarction, Myocardial Dysfunction
Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility
The purpose of this study is to evaluate whether late recanalization in patients with ST elevation myocardial infarction (STEMI) without Viability on Cardiovascular Magnetic Resonance Image (MRI) can reduce the reverse remodeling…
- Conditions
- STEMI - ST Elevation Myocardial Infarction, Myocardial Dysfunction, Percutaneous Coronary Intervention
- Trial name
- NCT05160311
- Testing
- Optimized Medical Treatment (OMT), Drug Eluting Stent (DES) Coronary Angioplasty
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
- Trial name
- COOPERATION (NCT04912518)
- Testing
- Dexmedetomidine (DEX)
- Where
- 9 sites in China
- Volunteers
- 250 people
- Sponsor
- Harbin Medical University
STEMI
Platelet Inhibition to Target Reperfusion Injury
There remains a clinical need to improve health outcomes in patients with ischemic heart disease (IHD) the leading cause of death and disability in Singapore and worldwide.
- Trial name
- PITRI (NCT03102723)
- Testing
- Cangrelor
- Where
- 5 sites in Singapore
- Volunteers
- 228 people
- Sponsor
- National Heart Centre Singapore
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
STEMI, Oxidative Stress
Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI
The investigators intend to evaluate Oxidative Stress biomarkers through a. Catalase Activity Assay; b. Lipid Peroxidation Assay; c. SOD Assay; d. Total Antioxidant Capacity Assay; e.
- Conditions
- STEMI, Oxidative Stress, Oxidative Stress Induction, Primary PCI
- Trial name
- OxiSTEMIhFABP (NCT04034940)
- Testing
- Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Acute Myocardial Infarction, Heart Failure
Inflammation-mediated Coronary Plaque Vulnerability, Myocardial Viability and Ventricular Remodeling
VIABILITY study aims to investigate the link between systemic inflammation, pancoronary plaque vulnerability (referring to the plaque vulnerability within the entire coronary tree), myocardial viability and ventricular remodeling…
- Trial name
- VIABILITY (NCT03830944)
- Testing
- Blood sampling, transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Cardio Med Medical Center
Acute Myocardial Infarction
Impact of OCT on Outcomes in AMI
This protocol describes a retrospective, single-center study intended to test the impact of optical coherence tomography(OCT) on long term clincical outcomes in patients with acute myocardial infarction(AMI).
- Trial name
- NCT05266547
- Testing
- OCT guided coronary intervention
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Beijing Luhe Hospital
Myocardial Infarction
Timing for Bone Marrow Mononuclear Cells After Acute Myocardial Infarction
Most studies on intracoronary bone marrow mononuclear cell (BMC) transplantation for acute myocardial infarction (AMI) involve treatment 3-7 days after primary percutaneous coronary intervention (PCI); however, the optimal timing…
- Trial name
- NCT02425358
- Testing
- BMC therapy within 24 hours, BMC therapy within 3-7 days, BMC therapy within 7-30 days
- Volunteers
- 104 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI)
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
This study is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. A total of 2,000 patients with STEMI (<24 hours or 7-14 days) or NSTEMI will be recruited from at least 20 centers in China.
- Conditions
- Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
- Trial name
- NCT07567625
- Testing
- Guideline-recommended standard medical therapy alone, DES implantation plus guideline-recommended standard medical therapy
- Where
- 48 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Harbin Medical University
STEMI
Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI
This is a retrospective, randomized, parallel, open-labeled, controlled study to find out whether STEMI patients undergoing emergency PCI can benefit from intensive atorvastatin treatment compared with routine treatment.
- Trial name
- NCT01033058
- Testing
- atorvastatin
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Chao Yang Hospital
ST Elevation Myocardial Infarction
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
As an effective treatment for acute ST-segment elevation myocardial infarction (STEMI), early reperfusion may reduce the infarct size and improve the prognosis of patients.
- Trial name
- OPTIMA-6 (NCT05410925)
- Testing
- Recombinant staphylokinase
- Where
- 61 sites in China
- Volunteers
- 2,260 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
STEMI, Emergent PCI
Evaluation of Antithrombotic STrategies in STEMI Patients in China
EAST-STEMI is the first perspective, multicenter, large-scale registry focusing on the evaluation of real-world medical quality (especially PCI quality) and antithrombotic strategies in STEMI patients undergoing emergent PCI in a…
- Trial name
- EAST-STEMI (NCT03510832)
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Qilu Hospital of Shandong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.